Cutaneous Adverse Drug Reactions (CADRs) to COVID19 vaccines: A case series

Viral vector vaccines (Covishield) and inactivated vaccines (Covaxin) are now being administered worldwide to reduce the impact of life-threatening corona virus disease 19 (COVID-19). Various cutaneous adverse drug reactions (CADRs) have been reported following COVID-19 vaccination. Here, we are rep...

Full description

Saved in:
Bibliographic Details
Main Authors: Manila Purushottam (Author), Vinutha Rangappa (Author), Jayadev B Betkerur (Author), Ashwini P Kombettu (Author), Veeranna Shastry (Author)
Format: Book
Published: Wolters Kluwer Medknow Publications, 2023-01-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_d5409e8c21eb484688de50efea860831
042 |a dc 
100 1 0 |a Manila Purushottam  |e author 
700 1 0 |a Vinutha Rangappa  |e author 
700 1 0 |a Jayadev B Betkerur  |e author 
700 1 0 |a Ashwini P Kombettu  |e author 
700 1 0 |a Veeranna Shastry  |e author 
245 0 0 |a Cutaneous Adverse Drug Reactions (CADRs) to COVID19 vaccines: A case series 
260 |b Wolters Kluwer Medknow Publications,   |c 2023-01-01T00:00:00Z. 
500 |a 2229-5178 
500 |a 10.4103/idoj.idoj_109_22 
520 |a Viral vector vaccines (Covishield) and inactivated vaccines (Covaxin) are now being administered worldwide to reduce the impact of life-threatening corona virus disease 19 (COVID-19). Various cutaneous adverse drug reactions (CADRs) have been reported following COVID-19 vaccination. Here, we are reporting series of CADRs following COVID-19 vaccination. Among 18 CADRs, 4 each were of acute urticaria and pityriasis rosea, 2 each of leukocytoclastic vasculitis and herpes zoster, 3 exacerbation of psoriasis, and 1 each of exacerbation of eczema, reactivation of herpes simplex virus 1 infection, and COVID arm. However, in 1 case there was remission of psoriasis. These CADRs occurred between 6 hours and 20 days after vaccination and were mild to moderate in severity. Only 1 needed hospitalization. Of the 18 CADRs, 10 developed after first dose and 8 after second dose. Causality assessment was done using World Health Organization causality assessment classification. Mass COVID-19 vaccination program is in progress worldwide. Many CADRs like COVID arm, urticaria, pityriasis rosea, leukocytoclastic vasculitis, herpes zoster etc., have been reported following vaccination. In our series only 1 developed cutaneous adverse drug reaction (CADR) to Covaxin. It was Covishield that was administered during the vaccination drive; hence, more cases were seen to that vaccine. Most of the CADRs were mild to moderate in intensity. Awareness of these adverse effects enables the healthcare professionals to be better equipped to recognize and manage them correctly. 
546 |a EN 
690 |a cadr 
690 |a covaxin 
690 |a covishield 
690 |a Dermatology 
690 |a RL1-803 
655 7 |a article  |2 local 
786 0 |n Indian Dermatology Online Journal, Vol 14, Iss 3, Pp 383-387 (2023) 
787 0 |n http://www.idoj.in/article.asp?issn=2229-5178;year=2023;volume=14;issue=3;spage=383;epage=387;aulast=Purushottam 
787 0 |n https://doaj.org/toc/2229-5178 
856 4 1 |u https://doaj.org/article/d5409e8c21eb484688de50efea860831  |z Connect to this object online.